Fig. 1
K284-6111 improves memory impairment in Aβ1–42-infused mice. a Timeline depicts the treatment of K284-6111 and assessments of the cognitive functions of mice. The male mice (n = 10) were orally treated with K284-6111 at a daily dose of 3 mg/kg for 4 weeks. After infusion of Aβ1–42 (300 pmol/day) for 14 days, memory tests were conducted. The training trial was performed two times a day for 7 days. Swimming time (b) and swimming distance (c) to the platform were automatically recorded. The time spent in the target quadrant and target site crossing within 60 s were represented (d). To perform the passive avoidance test, step-through method was used (e). Each value is presented as mean ± S.D. from 10 male mice. #Significant difference to control mice (P < 0.05), *Significant difference to Aβ1–42-injected mice (P < 0.05)